<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Rural Med</journal-id><journal-id journal-id-type="iso-abbrev">J Rural Med</journal-id><journal-id journal-id-type="publisher-id">JRM</journal-id><journal-title-group><journal-title>Journal of Rural Medicine : JRM</journal-title></journal-title-group><issn pub-type="ppub">1880-487X</issn><issn pub-type="epub">1880-4888</issn><publisher><publisher-name>The Japanese Association of Rural Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25649195</article-id><article-id pub-id-type="pmc">4309358</article-id><article-id pub-id-type="publisher-id">5-165</article-id><article-id pub-id-type="doi">10.2185/jrm.5.165</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on
Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild
Hypertension</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ohbayashi</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Minatoguchi</surname><given-names>Shinya</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aoyama</surname><given-names>Takuma</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fujiwara</surname><given-names>Hisayoshi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label> Department of Internal Medicine, JA Gifu
Tohno-Kousei Hospital, Japan</aff><aff id="aff2"><label>2</label> Second Department of Internal Medicine, Gifu
University School of Medicine, Japan</aff><aff id="aff3"><label>3</label> Department of Internal Medicine, Hyogo
Prefectural Amagasaki Hospital, Japan</aff></contrib-group><author-notes><corresp>Correspondence to: Hiroyuki Ohbayashi, Department of Internal Medicine, JA Gifu
Tohno-Kousei Hospital, 76-1 Toki-cho, Mizunami City, Gifu 509-6101, Japan. E-mail: <email xlink:href="ohbayashi@nn.iij4u.or.jp">ohbayashi@nn.iij4u.or.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>12</month><year>2010</year></pub-date><pub-date pub-type="ppub"><year>2010</year></pub-date><volume>5</volume><issue>2</issue><fpage>165</fpage><lpage>174</lpage><permissions><copyright-statement>&#x000a9;2010 The Japanese Association of Rural Medicine</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p><bold>Objective:</bold> The comparative effect of telmisartan and valsartan upon insulin
resistance and adipocytokines in nondiabetic patients with mild hypertension is
unclear.</p><p><bold>Methods:</bold> Fifty nondiabetic patients with untreated mild hypertension were
randomly assigned to telmisartan (40 mg/day) and valsartan (80 mg/day) groups and were
switched in a crossover manner at 3-month intervals. Serum leptin, adiponectin, hsCRP and
the HOMA-R were measured before and at 3 months during each treatment period.</p><p><bold>Results:</bold> The HOMA-R significantly improved over the 3 months in the high
insulin resistance group (HOMA-R&#x0003e;/=2.5) during the telmisartan treatment period
(p=0.042), but not during the valsartan period. Both telmisartan and valsartan
significantly decreased serum leptin levels in each female group during each treatment
period (p&#x0003c;0.001 and p&#x0003c;0.001, respectively), but not in the male groups. Serum
adiponectin did not increase in either treatment group. Serum hsCRP levels also
significantly decreased in the high hsCRP subjects (&#x0003e;/=0.1) of both treatment groups
(p=0.044 and p=0.015, respectively).</p><p><bold>Conclusions:</bold> Telmisartan significantly improved insulin resistance, possibly
through the effect on PPAR-gamma, while both telmisartan and valsartan significantly
decreased serum leptin levels in female groups and hsCRP in both genders, suggesting no
significantly different effects on adipocytokines by either drug in nondiabetic patients
with mild hypertension.</p></abstract><kwd-group><kwd>telmisartan</kwd><kwd>valsartan</kwd><kwd>leptin</kwd><kwd>insulin resistance</kwd><kwd>adiponectin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Peroxisome proliferator-activated receptor gamma (PPAR-gamma) plays a pivotal role in
progressing insulin resistance and cardiovascular diseases including hypertension<sup><xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>)</sup>.
Activation of PPAR-gamma may become a new therapeutic target to prevent hypertensive
vascular, renal and perhaps brain changes in hypertension<sup><xref rid="r3" ref-type="bibr">3</xref>)</sup>. A recent study by Bensen <italic>et al.</italic> demonstrated that
telmisartan, a structurally unique angiotensin II type 1 receptor blocker (ARB), can
function as a partial agonist of PPARgamma, while no other commercially available ARBs
appeared to activate PPARgamma<sup><xref rid="r4" ref-type="bibr">4</xref>)</sup>. In that
study, telmisartan activated the expression of the PPARgamma gene involved in carbohydrate
and lipid metabolism and reduced glucose, insulin and triglyceride levels in rats fed a
high-fat and high-carbohydrate diet. In humans, Pershadsingh <italic>et al.</italic> first
reported that 80 mg/day of telmisartan improved insulin resistance and reduced plasma
triglycerides in a male patient with hypertension, visceral obesity (BMI 34.4
kg/m<sup>2</sup>) and impaired glucose tolerance (prediabetes)<sup><xref rid="r5" ref-type="bibr">5</xref>)</sup>. When the patient was switched to valsartan, the improvement of
metabolic changes reversed. Then, switching back to telmisartan improved insulin sensitivity
again<sup><xref rid="r5" ref-type="bibr">5</xref>)</sup>. This suggested that
telmisartan predominantly improved insulin resistance compared with valsartan.</p><p>In addition to the effects of telmisartan on insulin resistance, it has recently been
reported that telmisartan also affected adipocytokines such as leptin and adiponectin.
Leptin is a 167-amino-acid-containing peptide that is specifically produced and secreted by
mature adipocyte<sup><xref rid="r6" ref-type="bibr">6</xref>)</sup>. This adipocyte-derived
protein acts in the hypothalamus to control appetite, energy expenditure and sympathetic
nervous system outflow. Previous studies showed the close relationship of leptin with
obesity and insulin resistance<sup><xref rid="r7" ref-type="bibr">7</xref>)</sup>. A very
recent study by Usui <italic>et al.</italic> demonstrated that 20&#x02013;40 mg of telmisartan for 3
or 6 months significantly reduced the fasting insulin level and the insulin resistance index
estimated using homeostasis model assessment (HOMA-R) and that serum leptin significantly
increased within 3 months in outpatients with both hypertension and type 2 diabetes mellitus
for 6 months<sup><xref rid="r8" ref-type="bibr">8</xref>)</sup>. However, whether
telmisartan affects the leptin level in the common nondiabetic patient with hypertension is
unclear.</p><p>Adiponectin is a 30-kDa protein that is also specifically produced and secreted by mature
adipocytes. Telmisartan treatment is considered to beneficially increase serum adiponectin.
A recent study by Clasen <italic>et al.</italic> indicated that telmisartan induced
adiponectin in adipocytes, which was associated with an improvement of parameters of insulin
sensitivity and was likely mediated via PPARgamma activation involving a
post-transcriptional mechanism<sup><xref rid="r9" ref-type="bibr">9</xref>)</sup>.
Telmisartan treatment also decreased the weight of visceral adipose tissue and improved
hyperglycemia, hyperinsulinemia, and hypertriglyceridemia in diet-induced obese mice while
also increasing the serum adiponectin and uncoupling protein 1 levels and reducing the serum
resistin level<sup><xref rid="r10" ref-type="bibr">10</xref>)</sup>. However, the effect of
telmisartan on increasing the serum adiponectin level was not sufficiently investigated in
the common nondiabetic patient with hypertension.</p><p>The aim of this randomized crossover study was to evaluate the effects of telmisartan on
improving insulin resistance and adipocytokines compared with valsartan, another major
commercialized ARB available worldwide, in common nondiabetic outpatients with mild
hypertension.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec><title>Subjects of the study</title><p>The study was approved by the ethics committees of Gifu University and Tohno-Kousei
Hospital, and all patients gave written informed consent. The clinical significance and
purpose of the study and the possible disadvantages of participation associated with
switching medications in a crossover manner were explained in detail to each patient.
Before enrollment in the study, we excluded patients who met the following exclusion
criteria: 1)previous usage of the ARBs, 2) taking any medication considered to affect the
PPAR and insulin resistance such as pioglitazone and fibrates, 3) taking medication for
chronic heart diseases, 4) severe hepatic, respiratory or renal disease, failure,
hematologic diseases or other grave complications, 5) oral steroid use and 6) history of
poor drug compliance.</p><p>The subjects enrolled in the study were 50 nondiabetic outpatients with untreated mild
hypertension. According to the guideline of the Japanese Society of Hypertension, values
for systolic blood pressure of 140&#x02013;159 mmHg or diastolic blood pressure of 90&#x02013;99 mmHg are
diagnosed as mild hypertension. After obtaining full informed consent from each
participant, the participants were randomly divided into two groups, the initial
telmisartan group and the initial valsartan group. The study subjects in the initial
telmisartan group were treated with 40 mg/day of telmisartan for the first 3 months and
were switched to a therapeutically equivalent dose of valsartan (80 mg/day) for the next 3
months. In contrast, those in the initial valsartan group were treated with 80 mg/day of
valsartan for the first 3 months and then 40 mg/day of telmisartan for the next 3 months.
Other kinds of medications used before the study, were allowed as concurrently taken drugs
during the study, with the doses of these drugs being kept constant throughout the study
periods. This study was carried out in accordance with the principles embodied in the
Helsinki Declaration of 1995 (as revised in Edinburgh 2000).</p></sec><sec><title>Study protocol (<xref ref-type="fig" rid="fig_001">Figure 1A</xref>)</title><p>The protocol of the study is shown in <xref ref-type="fig" rid="fig_001">Figure
1A</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Figure 1.</label><caption><p> (A) Study protocol and (B) Flow chart of study participants.</p></caption><graphic xlink:href="jrm-5-165-g001"/></fig>. Blood pressure was measured twice after resting for more than 15 minutes, and the
lesser value was chosen. Each subject was examined for serum leptin, adiponectin and high
sensitive C reactive protein (hsCRP), together with ordinary blood laboratory examinations
including hepatic function and cholesterols, before, at one and three months after the
start of the study and at three months after switching to the other ARB. The HOMA-R was
used as the index of insulin resistance (a value of more than 2.5 is considered to
indicate existence of insulin resistance). A fasting venous blood sample was obtained to
measure blood laboratory data such as the plasma levels of cholesterols and glucose. These
assays were performed using an automated analyzer (TBA-120FR, Toshiba, Tokyo, Japan). Each
patient&#x02019;s serum was immediately frozen at &#x02013;70&#x000ba;C, and serum adipocytokines were measured
within 24 hours. Serum levels of leptin, adiponectin and hsCRP were measured using a
leptin RIA kit (Linco Research, Inc., St. Charles, MO, USA), adiponectin ELISA kit (Otsuka
Pharmaceutical Co., Ltd., Tokyo, Japan) and N-latex CRP II kit (Dade Behring, Deerfield,
IL, USA), respectively. The heights (measured to the nearest 0.1 cm), weights (measured to
the nearest 0.1 kg) and waist circumferences (measured to the nearest 0.1 cm) of the
subjects were measured by the same trained staff. Waist circumference was measured
horizontally at the level of the umbilicus.</p></sec><sec><title>Statistical analyses</title><p>The significance level was set at 5%. Values of blood pressure, major blood laboratory
data, BMI and waist circumference are presented as means &#x000b1; SD. Comparisons between the
initial telmisartan and initial valsartan groups in <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1</label><caption><title> Patient characteristics</title></caption><graphic xlink:href="jrm-5-165-t001"/></table-wrap> were analyzed using Fisher&#x02019;s exact test or the Mann-Whitney U test. Values
of serum leptin, adiponectin, hsCRP and the HOMA-R index are presented as median and 25&#x02013;75
percentiles. Statistical differences of blood pressure were analyzed by repeated measures
one-way ANOVA and the Scheffe method as a post hoc test. Time-course changes in leptin,
adiponectin, hsCRP, HOMA-R index and major blood laboratory tests were analyzed by the
Friedman test and Wilcoxon signed-rank test with Bonferroni&#x02019;s correction. Correlation
between changes in &#x00394;leptin levels and &#x00394;HOMA-R indexes for 3 months was examined with
Spearman rank correlation. Statistical analyses were carried out using JMP, version 5.1.2
(SAS Institute Inc., Cary, NC, USA).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Subjects</title><p>Ultimately, 42 nondiabetic patients with mild hypertension completed the study (<xref ref-type="fig" rid="fig_001">Figure 1B</xref>). Patient characteristics are shown in
<xref rid="tbl_001" ref-type="table">Table 1</xref>. There was no statistical
significance concerning the major indexes between the initial telmisartan and initial
valsartan groups at enrollment in the study. During the study, the 42 subjects did not
complain of any side effects.</p></sec><sec><title>Comparison of blood pressure between the two groups (<xref ref-type="fig" rid="fig_002">Figure 2</xref>)</title><p>Time-course changes in systolic and diastolic blood pressure in both groups are shown in
<xref ref-type="fig" rid="fig_002">Figure 2</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Figure 2.</label><caption><p> Time-course changes in systolic and diastolic blood pressures over the study
period. Statistical significance: *p&#x0003c;0.05, **p&#x0003c;0.01 and ***p&#x0003c;0.001 compared
with the values at the start of the study.</p></caption><graphic xlink:href="jrm-5-165-g002"/></fig>. In the initial telmisartan group, both the systolic and diastolic blood pressures
were significantly improved one month after administration. This significant improvement
in both blood pressures remained at three months after switching to valsartan. On the
other hand, the changes in the systolic blood pressure were significantly decreased
beginning one month after administration of valsartan in the initial valsartan group,
while the diastolic blood pressure was not improved during the study period. As shown in
<xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2</label><caption><title> Comparative effects of telmisartan and valsartan during each 3 months
treatment period</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="2"/><th align="center" valign="middle" colspan="2" rowspan="1">duration of telmisartan
treatment<hr/></th><th align="center" valign="middle" colspan="2" rowspan="1">duration of valsartan
treatment<hr/></th><th align="center" valign="middle" rowspan="2" colspan="1">p value
(statistical<break/> significance<break/>between both groups)</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">&#x00394;</th><th align="center" rowspan="1" colspan="1">p value (statistical<break/>significance<break/>compared with 0
M)</th><th align="center" valign="middle" rowspan="1" colspan="1">&#x00394;</th><th align="center" rowspan="1" colspan="1">p value (statistical<break/>significance<break/>compared with 0
M)</th></tr></thead><tbody><tr><td align="left" valign="middle" colspan="7" rowspan="1">&#x00394; SBP (mmHg)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">female</td><td align="center" rowspan="1" colspan="1">&#x02013;15.5 &#x000b1; 9.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001 (***)</td><td align="center" rowspan="1" colspan="1">&#x02013;9.7 &#x000b1; 15.3</td><td align="center" rowspan="1" colspan="1">0.005 (**)</td><td align="center" rowspan="1" colspan="1">0.122</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">male</td><td align="center" rowspan="1" colspan="1">&#x02013;17.5 &#x000b1; 10.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001 (***)</td><td align="center" rowspan="1" colspan="1">&#x02013;18.1 &#x000b1; 10.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001 (***)</td><td align="center" rowspan="1" colspan="1">0.874</td></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">&#x00394; DBP (mmHg)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">female</td><td align="center" rowspan="1" colspan="1">&#x02013;7.5 &#x000b1; 6.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001 (***)</td><td align="center" rowspan="1" colspan="1">&#x02013;2.1 &#x000b1; 8.6</td><td align="center" rowspan="1" colspan="1">0.232</td><td align="center" rowspan="1" colspan="1">0.018 (*)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">male</td><td align="center" rowspan="1" colspan="1">&#x02013;6.5 &#x000b1; 8.3</td><td align="center" rowspan="1" colspan="1">0.004 (**)</td><td align="center" rowspan="1" colspan="1">&#x02013;8.1 &#x000b1; 6.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001 (***)</td><td align="center" rowspan="1" colspan="1">0.529</td></tr><tr><td align="left" colspan="7" rowspan="1">&#x00394; HOMA-R</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">female</td><td align="center" rowspan="1" colspan="1">&#x02013;0.4 (&#x02013;0.5, 0.3)</td><td align="center" rowspan="1" colspan="1">0.391</td><td align="center" rowspan="1" colspan="1">&#x02013;0.2 (&#x02013;0.4, 0.4)</td><td align="center" rowspan="1" colspan="1">0.346</td><td align="center" rowspan="1" colspan="1">0.853</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">male</td><td align="center" rowspan="1" colspan="1">0.0 (&#x02013;0.1, 0.3)</td><td align="center" rowspan="1" colspan="1">0.632</td><td align="center" rowspan="1" colspan="1">&#x02013;0.0 (&#x02013;0.4, 0.3)</td><td align="center" rowspan="1" colspan="1">0.795</td><td align="center" rowspan="1" colspan="1">0.704</td></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">&#x00394; HOMA-R</td></tr><tr><td align="left" valign="middle" colspan="2" style="padding-left:15pt" rowspan="1">(initaial
value &#x0003e;/=2.5)</td><td align="center" rowspan="1" colspan="1">&#x02013;0.3 (&#x02013;0.7, &#x02013;0.1)</td><td align="center" rowspan="1" colspan="1">0.042 (*)</td><td align="center" rowspan="1" colspan="1">&#x02013;0.8 (&#x02013;1.4, &#x02013;0.0)</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.529</td></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">&#x00394; leptin (ng/dL)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">female</td><td align="center" rowspan="1" colspan="1">&#x02013;2.7 (&#x02013;4.0, &#x02013;0.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001 (***)</td><td align="center" rowspan="1" colspan="1">&#x02013;2.5 (&#x02013;4.5, &#x02013;0.5)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001 (***)</td><td align="center" rowspan="1" colspan="1">0.853</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">male</td><td align="center" rowspan="1" colspan="1">&#x02013;0.6 (&#x02013;2.4, &#x02013;0.5)</td><td align="center" rowspan="1" colspan="1">0.106</td><td align="center" rowspan="1" colspan="1">&#x02013;0.8 (&#x02013;1.6, &#x02013;0.0)</td><td align="center" rowspan="1" colspan="1">0.356</td><td align="center" rowspan="1" colspan="1">0.558</td></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">&#x00394; adiponectin (ng/dL)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">female</td><td align="center" rowspan="1" colspan="1">&#x02013;1.1 (&#x02013;1.8, &#x02013;0.69)</td><td align="center" rowspan="1" colspan="1">0.004 (**)</td><td align="center" rowspan="1" colspan="1">&#x02013;0.9 (&#x02013;2.6, 0.5)</td><td align="center" rowspan="1" colspan="1">0.004 (**)</td><td align="center" rowspan="1" colspan="1">0.948</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">male</td><td align="center" rowspan="1" colspan="1">&#x02013;0.18 (&#x02013;1.1, &#x02013;0.75)</td><td align="center" rowspan="1" colspan="1">0.632</td><td align="center" rowspan="1" colspan="1">&#x02013;0.1 (&#x02013;0.7, 0.7)</td><td align="center" rowspan="1" colspan="1">0.948</td><td align="center" rowspan="1" colspan="1">0.987</td></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">&#x00394; hsCRP (mg/dL)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">female</td><td align="center" rowspan="1" colspan="1">&#x02013;0.002 (&#x02013;0.018, 0.010)</td><td align="center" rowspan="1" colspan="1">0.346</td><td align="center" rowspan="1" colspan="1">0.002 (&#x02013;0.036, 0.011)</td><td align="center" rowspan="1" colspan="1">0.438</td><td align="center" rowspan="1" colspan="1">0.869</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">male</td><td align="center" rowspan="1" colspan="1">&#x02013;0.004 (&#x02013;0.123, 0.032)</td><td align="center" rowspan="1" colspan="1">0.317</td><td align="center" rowspan="1" colspan="1">0.002 (&#x02013;0.116, 0.040)</td><td align="center" rowspan="1" colspan="1">0.557</td><td align="center" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" valign="middle" colspan="7" rowspan="1">&#x00394; hsCRP (mg/dL)</td></tr><tr><td align="left" valign="middle" colspan="2" style="padding-left:15pt" rowspan="1">(initial
value &#x0003e;/= 0.1)</td><td align="center" rowspan="1" colspan="1">&#x02013;0.100 (&#x02013;0.150, 0.042)</td><td align="center" rowspan="1" colspan="1">0.044 (*)</td><td align="center" rowspan="1" colspan="1">&#x02013;0.107 (&#x02013;0.153, &#x02013;0.036)</td><td align="center" rowspan="1" colspan="1">0.015 (*)</td><td align="center" rowspan="1" colspan="1">0.763</td></tr></tbody></table></table-wrap>, there were significant decreases in systolic blood pressure during each
3-month treatment period for telmisartan and valsartan. However, there was no statistical
difference in the &#x00394;SBP (3 months changes in systolic blood pressure) between both ARBs in
males and females (p=0.122 and p=0.874, respectively). On the other hand, there were also
significant improvements in the &#x00394;DBP in both males and females in the telmisartan
treatment group (p=0.004 and p&#x0003c;0.001, respectively), but there was no significant
improvement in the &#x00394;DBP in the female valsartan group (p=0.232). Accordingly, there was a
significant difference in the &#x00394;DBP between the female telmisartan and valsartan treatment
groups (p=0.018).</p></sec><sec><title>Changes in insulin resistance</title><p>During the treatment period with telmisartan, although the changes were not significant,
the values of IRI decreased from 9.4 &#x000b1; 8.6 to 8.1 &#x000b1; 13.4 (IU/L). The changes in the IRI
tended to be remarkable in the high insulin resistance group (HOMA-R &#x0003e;/= 2.5), from
17.2 &#x000b1; 10.9 to 13.1 &#x000b1; 12.6 (IU/L; p=0.412). On the other hand, we found no change in the
IRI during valsartan treatment period, from 8.5 &#x000b1; 3.9 to 8.6 &#x000b1; 4.7 (IU/L). We found no
significant changes in the FBS values in both the telmisartan and valsartan treatment
periods. As shown in <xref ref-type="fig" rid="fig_003">Figure 3 (A)</xref><fig orientation="portrait" fig-type="figure" id="fig_003" position="float"><label>Figure 3.</label><caption><p> Time-course changes in (A) the HOMA-R indexes, (B) serum leptin levels, (C) serum
adiponectin levels and (D) serum hsCRP levels over the study period. Statistical
significance: *p/3&#x0003c;0.05 and **p/3&#x0003c;0.01 compared with the values at the start
of the study.</p></caption><graphic xlink:href="jrm-5-165-g003"/></fig>, telmisartan significantly improved the levels of HOMA-R in the high insulin
resistance group (the HOMA-R &#x0003e;/= 2.5) at one month after administration, while
valsartan did not. In the high insulin resistance group of the initial valsartan group,
the HOMA-R tended to decrease 3 months after changing from valsartan to telmisartan. In
contrast, there were no statistically significant differences in either lower insulin
resistance group (HOMA-R &#x0003c; 2.5). Furthermore, when evaluating the changes in the HOMA-R
together with the male and female groups in each ARB treatment group, telmisartan
significantly improved the &#x00394;HOMA-R during the 3-month treatment periods, but valsartan did
not (<xref rid="tbl_002" ref-type="table">Table 2</xref>).</p></sec><sec><title>Changes in serum adipocytokines and hsCRP levels</title><p>As shown in <xref ref-type="fig" rid="fig_003">Figure 3 (B)</xref>, the serum leptin
levels significantly improved at 3 months of the treatment in both female ARB groups
(p=0.004 and p=0.009 compared with those at the start of the study, respectively). The
significant improvement of serum leptin was lost three months after switching to valsartan
in the female initial telmisartan group. In contrast, the significant improvement of the
serum leptin levels at three months in the female initial valsartan group remained three
months after changing to telmisartan (p=0.011). On the other hand, there were no
significant changes in both male groups. <xref rid="tbl_002" ref-type="table">Table
2</xref> shows that the &#x00394;leptin over 3 months significantly decreased in both female ARB
treatment groups, while it did not in the male groups. There was no significant difference
in the value of &#x00394;leptin between the telmisartan and valsartan treatments for each 3-months
period (<xref rid="tbl_002" ref-type="table">Table 2</xref>). Serum adiponectin did not
increase in both treatment groups.</p><p>The changes in hsCRP levels significantly decreased over the study period in the initial
telmisartan group (p=0.019), while they did not in the initial valsartan group (p=0.266;
<xref ref-type="fig" rid="fig_003">Figure 3 (C)</xref>). Serum hsCRP was significantly
improved after three months of treatment with telmisartan and significantly worsened at 3
months after the switch to valsartan. When selecting the subjects according to an initial
hsCRP level of at least 0.1 mg/dL, we found a significant decrease in the value of &#x00394;hsCRP
over 3 months in both ARB treatment groups (<xref rid="tbl_002" ref-type="table">Table
2</xref>).</p></sec><sec><title>Correlation to each index</title><p>The initial leptin levels at the start of the study were significantly correlated to the
initial values of HOMA-R in both the male (p=0.001, R<sup>2</sup>=0.490, n=18 in total for
both ARB groups) and female groups (p=0.002, R<sup>2</sup>=0.355, n=24 in total for both
ARBs groups), respectively. As shown in <xref ref-type="fig" rid="fig_004">Figure
4</xref><fig orientation="portrait" fig-type="figure" id="fig_004" position="float"><label>Figure 4.</label><caption><p> Correlation between change in leptin levels and the HOMA-R indexes for 3
months.</p></caption><graphic xlink:href="jrm-5-165-g004"/></fig>, the &#x00394;HOMA-R (3M-0M) was significantly correlated to the &#x00394;Leptin (3 M-0 M) in the
female initial telmisartan group (p=0.021, R<sup>2</sup>=0.308 ), while it was not in the
male initial telmisartan group and both initial valsartan groups. Furthermore, in this
study, although we investigated the correlation among HOMA-R, leptin, adiponectin, hsCRP
and blood pressure, we found no significant relationship in either ARB group (data not
shown).</p></sec><sec><title>Changes in blood laboratory examinations (<xref rid="tbl_003" ref-type="table">Table
3</xref>)</title><p><xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3</label><caption><title> Time-course changes in major blood laboratory indexes over the study</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="center" valign="middle" colspan="5" rowspan="1">Initial Telmisartan group<hr/></th><th align="center" valign="middle" colspan="5" rowspan="1">Initial Valsartan group<hr/></th><th align="center" valign="middle" rowspan="3" colspan="1">Statistical significance<break/>
between two groups<break/>(0 M-3 M) (p value)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">cross</th><th align="center" rowspan="2" colspan="1">Statistical significance<break/>(p
value)</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">cross</th><th align="center" rowspan="2" colspan="1">Statistical significance<break/>(p
value)</th></tr><tr><th align="center" rowspan="1" colspan="1">0 M</th><th align="center" rowspan="1" colspan="1">1 M</th><th align="center" rowspan="1" colspan="1">3 M</th><th align="center" rowspan="1" colspan="1">3 M</th><th align="center" rowspan="1" colspan="1">0 M</th><th align="center" rowspan="1" colspan="1">1 M</th><th align="center" rowspan="1" colspan="1">3 M</th><th align="center" rowspan="1" colspan="1">3 M</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">UA (IU/L)</td><td align="center" rowspan="1" colspan="1">5.36 &#x000b1; 1.51</td><td align="center" rowspan="1" colspan="1">5.42 &#x000b1; 1.37</td><td align="center" rowspan="1" colspan="1">5.55 &#x000b1; 1.43</td><td align="center" rowspan="1" colspan="1">5.32 &#x000b1; 1.40</td><td align="center" rowspan="1" colspan="1">0.134</td><td align="center" rowspan="1" colspan="1">5.41 &#x000b1; 1.17</td><td align="center" rowspan="1" colspan="1">5.38 &#x000b1; 1.32</td><td align="center" rowspan="1" colspan="1">5.55 &#x000b1; 1.20</td><td align="center" rowspan="1" colspan="1">5.39 &#x000b1; 1.19</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">0.923</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (IU/L)</td><td align="center" rowspan="1" colspan="1">25.4 &#x000b1; 12.3</td><td align="center" rowspan="1" colspan="1">23.6 &#x000b1; 9.8 (<sup>&#x02020;</sup>)</td><td align="center" rowspan="1" colspan="1">23.1 &#x000b1; 7.5</td><td align="center" rowspan="1" colspan="1">25.8 &#x000b1; 9.1 (*)</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">26.3 &#x000b1; 8.6</td><td align="center" rowspan="1" colspan="1">25.1 &#x000b1; 6.6</td><td align="center" rowspan="1" colspan="1">26.9 &#x000b1; 9.3</td><td align="center" rowspan="1" colspan="1">29.3 &#x000b1; 18.5</td><td align="center" rowspan="1" colspan="1">0.671</td><td align="center" rowspan="1" colspan="1">0.301</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (IU/L)</td><td align="center" rowspan="1" colspan="1">22.7 &#x000b1; 13.4</td><td align="center" rowspan="1" colspan="1">20.2 &#x000b1; 10.6</td><td align="center" rowspan="1" colspan="1">21.0 &#x000b1; 10.2</td><td align="center" rowspan="1" colspan="1">24.4 &#x000b1; 14.2</td><td align="center" rowspan="1" colspan="1">0.185</td><td align="center" rowspan="1" colspan="1">24.6 &#x000b1; 12.4</td><td align="center" rowspan="1" colspan="1">24.2 &#x000b1; 12.2</td><td align="center" rowspan="1" colspan="1">26.4 &#x000b1; 13.7</td><td align="center" rowspan="1" colspan="1">29.2 &#x000b1; 25.6</td><td align="center" rowspan="1" colspan="1">0.367</td><td align="center" rowspan="1" colspan="1">0.321</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b3;-GTP (IU/L)</td><td align="center" rowspan="1" colspan="1">32.2 &#x000b1; 21.0</td><td align="center" rowspan="1" colspan="1">31.8 &#x000b1; 21.6</td><td align="center" rowspan="1" colspan="1">31.4 &#x000b1; 20.6</td><td align="center" rowspan="1" colspan="1">34.7 &#x000b1; 34.0</td><td align="center" rowspan="1" colspan="1">0.956</td><td align="center" rowspan="1" colspan="1">30.8 &#x000b1; 22.3</td><td align="center" rowspan="1" colspan="1">29.0 &#x000b1; 19.9</td><td align="center" rowspan="1" colspan="1">30.8 &#x000b1; 24.5</td><td align="center" rowspan="1" colspan="1">31.8 &#x000b1; 21.3</td><td align="center" rowspan="1" colspan="1">0.767</td><td align="center" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" rowspan="1" colspan="1">LDH (IU/L)</td><td align="center" rowspan="1" colspan="1">213.8 &#x000b1; 37.7</td><td align="center" rowspan="1" colspan="1">221.6 &#x000b1; 42.2</td><td align="center" rowspan="1" colspan="1">211.4 &#x000b1; 39.9</td><td align="center" rowspan="1" colspan="1">213.2 &#x000b1; 39.1</td><td align="center" rowspan="1" colspan="1">0.215</td><td align="center" rowspan="1" colspan="1">210.8 &#x000b1; 32.7</td><td align="center" rowspan="1" colspan="1">210.2 &#x000b1; 34.3</td><td align="center" rowspan="1" colspan="1">207.4 &#x000b1; 34.9</td><td align="center" rowspan="1" colspan="1">209.9 &#x000b1; 31.7</td><td align="center" rowspan="1" colspan="1">0.441</td><td align="center" rowspan="1" colspan="1">0.313</td></tr><tr><td align="left" rowspan="1" colspan="1">CK (IU/L)</td><td align="center" rowspan="1" colspan="1">117.5 &#x000b1; 69.7</td><td align="center" rowspan="1" colspan="1">124.5 &#x000b1; 70.0</td><td align="center" rowspan="1" colspan="1">113.2 &#x000b1; 84.3</td><td align="center" rowspan="1" colspan="1">112.8 &#x000b1; 53.3</td><td align="center" rowspan="1" colspan="1">0.091</td><td align="center" rowspan="1" colspan="1">124.2 &#x000b1; 78.6</td><td align="center" rowspan="1" colspan="1">127.5 &#x000b1; 61.0</td><td align="center" rowspan="1" colspan="1">113.0 &#x000b1; 62.3</td><td align="center" rowspan="1" colspan="1">123.0 &#x000b1; 84.9</td><td align="center" rowspan="1" colspan="1">0.802</td><td align="center" rowspan="1" colspan="1">0.747</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" rowspan="1" colspan="1">5.87 &#x000b1; 0.95</td><td align="center" rowspan="1" colspan="1">5.88 &#x000b1; 0.95</td><td align="center" rowspan="1" colspan="1">5.86 &#x000b1; 1.00</td><td align="center" rowspan="1" colspan="1">5.89 &#x000b1; 0.99</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">5.90 &#x000b1; 1.16</td><td align="center" rowspan="1" colspan="1">6.07 &#x000b1; 1.51</td><td align="center" rowspan="1" colspan="1">5.98 &#x000b1; 1.46</td><td align="center" rowspan="1" colspan="1">6.08 &#x000b1; 1.63</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0.593</td></tr><tr><td align="left" rowspan="1" colspan="1">Total Cho (mg/dL)</td><td align="center" rowspan="1" colspan="1">219.4 &#x000b1; 35.7</td><td align="center" rowspan="1" colspan="1">222.3 &#x000b1; 41.6</td><td align="center" rowspan="1" colspan="1">216.6 &#x000b1; 35.2</td><td align="center" rowspan="1" colspan="1">223.6 &#x000b1; 41.6</td><td align="center" rowspan="1" colspan="1">0.257</td><td align="center" rowspan="1" colspan="1">207.6 &#x000b1; 27.5</td><td align="center" rowspan="1" colspan="1">208.6 &#x000b1; 30.4</td><td align="center" rowspan="1" colspan="1">203.6 &#x000b1; 27.5</td><td align="center" rowspan="1" colspan="1">209.7 &#x000b1; 30.7</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">0.958</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C (mg/dL)</td><td align="center" rowspan="1" colspan="1">58.8 &#x000b1; 12.2</td><td align="center" rowspan="1" colspan="1">57.1 &#x000b1; 15.4 (<sup>&#x02020;</sup>)</td><td align="center" rowspan="1" colspan="1">54.7 &#x000b1; 13.8 (<sup>&#x02020;&#x02020;</sup>)</td><td align="center" rowspan="1" colspan="1">55.4 &#x000b1; 13.6 (<sup>&#x02020;&#x02020;</sup>)</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">57.8 &#x000b1; 17.2</td><td align="center" rowspan="1" colspan="1">55.8 &#x000b1; 15.2</td><td align="center" rowspan="1" colspan="1">52.1 &#x000b1; 15.7 (<sup>&#x02020;&#x02020;</sup>)</td><td align="center" rowspan="1" colspan="1">53.9. &#x000b1; 14.7 (<sup>&#x02020;</sup>)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-C (mg/dL)</td><td align="center" rowspan="1" colspan="1">126.6 &#x000b1; 39.5</td><td align="center" rowspan="1" colspan="1">129.7 &#x000b1; 43.5</td><td align="center" rowspan="1" colspan="1">123.6 &#x000b1; 38.8</td><td align="center" rowspan="1" colspan="1">129.0 &#x000b1; 43.2</td><td align="center" rowspan="1" colspan="1">0.528</td><td align="center" rowspan="1" colspan="1">117.7 &#x000b1; 25.5</td><td align="center" rowspan="1" colspan="1">118.2 &#x000b1; 26.7</td><td align="center" rowspan="1" colspan="1">113.2 &#x000b1; 28.0</td><td align="center" rowspan="1" colspan="1">114.4 &#x000b1; 31.4</td><td align="center" rowspan="1" colspan="1">0.692</td><td align="center" rowspan="1" colspan="1">0.693</td></tr><tr><td align="left" rowspan="1" colspan="1">TG (mg/dL)</td><td align="center" rowspan="1" colspan="1">143.4 &#x000b1; 95.3</td><td align="center" rowspan="1" colspan="1">152.3 &#x000b1; 119.0</td><td align="center" rowspan="1" colspan="1">155.9 &#x000b1; 116.8</td><td align="center" rowspan="1" colspan="1">143.3 &#x000b1; 91.3</td><td align="center" rowspan="1" colspan="1">0.303</td><td align="center" rowspan="1" colspan="1">127.5 &#x000b1; 72.0</td><td align="center" rowspan="1" colspan="1">151.7 &#x000b1; 93.0</td><td align="center" rowspan="1" colspan="1">160.0 &#x000b1; 111.7</td><td align="center" rowspan="1" colspan="1">164.8 &#x000b1; 132.7</td><td align="center" rowspan="1" colspan="1">0.377</td><td align="center" rowspan="1" colspan="1">0.921</td></tr></tbody></table><table-wrap-foot><p>*p/3&#x0003c;0.05 compared with the value at the three months after the start (the Wilcoxon
signed-rank test with Bonferroni&#x02019;s correction). &#x02020;p/3&#x0003c;0.05 and &#x02020;&#x02020;p/3&#x0003c;0.01 compared
with the value at the start of the study (the Wilcoxon signed-rank test with
Bonferroni&#x02019;s correction).</p></table-wrap-foot></table-wrap> shows time-course changes in major blood laboratory indexes over the study
period. The serum levels of AST significantly decreased in the initial telmisartan
treatment group. The levels of HDL-C also decreased in the both ARB groups.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this study, we evaluated the differences in the effects of telmisartan and valsartan
upon the insulin resistance, adipocytokines and inflammation in common nondiabetic patients
with mild hypertension. First, we showed that telmisartan significantly improved insulin
resistance in the HOMA-R &#x0003e;/= 2.5 group at one month after administration in nondiabetic
patients with mild hypertension, while valsartan did not (<xref ref-type="fig" rid="fig_003">Figure 3 (A)</xref>). Furthermore, HOMA-R tended to worsen after switching to treatment
with valsartan in this HOMA-R &#x0003e;/= 2.5 initial telmisartan group. These results are not
inconsistent with the report by Pershadsingh <italic>et al.</italic><sup><xref rid="r5" ref-type="bibr">5</xref>)</sup>. In addition, telmisartan beneficially had no influence on
insulin resistance in the normal range group (the HOMA-R&#x0003c;2.5). These findings suggest
that telmisartan can significantly and beneficially improve insulin resistance in common
nondiabetic patients with mild hypertension. A recent study by Benndorf <italic>et
al.</italic> showed that telmisartan improved insulin sensitivity in nondiabetic patients
with essential hypertension<sup><xref rid="r11" ref-type="bibr">11</xref>)</sup>. Another
very recent study by Ichikawa also showed that HOMA-R was significantly reduced by
telmisartan compared with the baseline value, but not by valsartan, in hypertensive patients
with metabolic syndrome<sup><xref rid="r12" ref-type="bibr">12</xref>)</sup>. Our findings
are consistent with those of the above studies. Although there was no significant difference
between the initial ARB groups in the present study, there may have been a tendency for
subjects who had high insulin resistance to be chosen in the initial valsartan group through
the first process of randomization. However, if valsartan has a sufficient effect upon the
improvement of insulin resistance, the drug should improve the HOMA-R in a prominent
situation compared with telmisartan.</p><p>As it is well-known that leptin is linked to insulin resistance<sup><xref rid="r7" ref-type="bibr">7</xref>)</sup>, we confirmed that the leptin levels were significantly
correlated with the initial values of HOMA-R in both the male and female groups at the start
of the study (p=0.001 and p=0.002, respectively). Furthermore, we found a significant gender
difference in leptin levels between the initial male and female groups; those of the women
were higher than those of the men in both the initial telmisartan and valsartan groups
(p=0.003 and p=0.005, respectively; <xref rid="tbl_001" ref-type="table">Table 1</xref>),
which is consistent with the results of Takizawa <italic>et al.</italic><sup><xref rid="r13" ref-type="bibr">13</xref>)</sup>. In the present study, we showed that both
telmisartan and valsartan significantly decreased the serum leptin levels in both female
groups, not but in the male groups (<xref rid="tbl_002" ref-type="table">Table 2</xref> and
<xref ref-type="fig" rid="fig_003">Figure 3 (B)</xref>). We also demonstrated that the
changes in HOMA-R over 3 months (&#x00394;HOMA-R) were significantly correlated with those of leptin
over 3 months (&#x00394;leptin) in the female initial telmisartan group, but not in the male
telmisartan group or either gender valsartan groups (<xref ref-type="fig" rid="fig_004">Figure 4</xref>). The above results suggest that the reductive effect of both ARBs on
leptin appeared to occur through a different mechanism from the improvement of insulin
resistance in common nondiabetic patients with mild hypertension.</p><p>According to the results of <italic>in vivo</italic> and animal model experiments<sup><xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r10" ref-type="bibr">10</xref>)</sup>,
we initially began the study with the anticipation that telmisartan would significantly
increase the serum adiponectin levels during the treatment period. However, the results in
this study showed that serum adiponectin did not increase in both ARB treatment groups
(<xref rid="tbl_002" ref-type="table">Table 2</xref>). This may be partly caused by the
dose-dependent effects of telmisartan. Although previous studies used 80 mg of
telmisartan<sup><xref rid="r5" ref-type="bibr">5</xref>)</sup>, we used only 40 mg/day of
telmisartan for the common nondiabetic patients with hypertension in this study. However, we
also showed the possibility that telmisartan may directly activate the PPAR-gamma receptor
and improve insulin resistance with an independent mechanism through adiponectin elevation.
A recent study by Usui <italic>et al.</italic> also demonstrated that 20&#x02013;40 mg of
telmisartan significantly reduced the HOMA-R for 3 or 6 months and significantly increased
serum leptin within 3 months in outpatients with both hypertension and type 2 diabetes
mellitus, and the authors reported that total and high molecular adiponectin, fasting plasma
glucose, HbA1c, total and HDLcholesterol, triglyceride, body weight, BMI and waist length
were unchanged<sup><xref rid="r14" ref-type="bibr">14</xref>)</sup>. Another study by
Benndor <italic>et al.</italic> also showed that telmisartan did not affect serum
adiponectin levels in nondiabetic patients with essential hypertension, in spite of
improving insulin sensitivity<sup><xref rid="r11" ref-type="bibr">11</xref>)</sup>. In
addition, they demonstrated that telmisartan significantly enhanced PPAR-gamma receptor
activity in vitro using a PPAR-gamma reporter gene assay, suggesting that telmisartan
improved insulin sensitivity by mechanisms apparently not involving adiponectin
induction<sup><xref rid="r11" ref-type="bibr">11</xref>)</sup>. A randomized,
placebo-controlled, double-blind and crossover study by Nagel <italic>et al.</italic> also
showed that 40 mg of telmisartan did not significantly increase the adiponectin level in
nondiabetic insulin-resistant subjects over 12 weeks compared with a placebo, instead of the
reduction of the HOMA-R<sup><xref rid="r15" ref-type="bibr">15</xref>)</sup>. A very recent
in vitro study by Moriuchi <italic>et al.</italic> indicated that the transcription of the
human adiponectin gene by telmisartan may be regulated by the independent mechanism of
PPAR-gamma<sup><xref rid="r16" ref-type="bibr">16</xref>)</sup>. Considering all the above
studies, the result in this study that telmisartan significantly improved insulin resistance
with no elevation of adiponectin may be consistent.</p><p>Both telmisartan and valsartan also significantly reduced the serum hsCRP levels in the
hsCRP level &#x0003e;/= 0.1 groups (<xref rid="tbl_002" ref-type="table">Table 2</xref>), but
telmisartan decreased the levels more effectively compared with valsartan (<xref ref-type="fig" rid="fig_003">Figure 3 (C)</xref>). Previous studies have shown the
anti-inflammatory effect of telmisartan. A previous study by Koulouris <italic>et
al.</italic> showed the same reductive effect of telmisartan on hsCRP in patients with
type 2 diabetes mellitus<sup><xref rid="r17" ref-type="bibr">17</xref>)</sup>.
Pathophysiological crosstalk between advanced glycation endproducts (AGEs) and their
receptor (RAGE) plays a pivotal role in the pathogenesis of accelerated atherosclerosis in
diabetes<sup><xref rid="r18" ref-type="bibr">18</xref>)</sup>. Telmisartan downregulated
RAGE mRNA and inhibited superoxide generation in mesangial cells via PPAR-gamma activation,
while Candesartan did not<sup><xref rid="r19" ref-type="bibr">19</xref>)</sup>. Another
study demonstrated that telmisartan decreased the serum levels of RAGE in patients with
essential hypertension<sup><xref rid="r20" ref-type="bibr">20</xref>)</sup>. A recent study
by Yoshida <italic>et al.</italic> showed that telmisartan dose-dependently inhibited
AGE-induced CRP expression in a human hepatoma cell line, which indicated that telmisartan
may play an anti-inflammatory role via PPAR-gamma activation<sup><xref rid="r21" ref-type="bibr">21</xref>)</sup>. Although the exact reason for the reductive effect on hsCRP in
this study is unclear, this reduction may be partly mediated by the inhibition of AGE via
PPAR-gamma activation.</p><p>In conclusion, this open-label, randomized crossover study showed that telmisartan
significantly and beneficially improved the high status of insulin resistance in common
nondiabetic patients with hypertension compared with valsartan. Telmisartan and valsartan
significantly decreased the serum leptin levels in the female group, but not in the male
group. However, we found no increase in the serum adiponectin levels during both ARB
treatment periods. Both telmisartan and valsartan also significantly reduced the high status
of serum hsCRP levels. These results may possibly be reflected by the difference in potency
of PPAR-gamma activation between telmisartan and valsartan.</p></sec></body><back><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Hsueh</surname><given-names>WA</given-names></name><name><surname>Law</surname><given-names>R</given-names></name></person-group>. <article-title>The central role of fat and effect of peroxisome
proliferator-activated receptor-gamma on progression of insulin resistance and
cardiovascular disease</article-title>. <source>Am J Cardiol</source><year>2003</year>. <volume>92</volume>: <fpage>3J</fpage>&#x02013;<lpage>9J</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/S0002-9149(03)00610-6</pub-id><pub-id pub-id-type="pmid">12957321</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Schiffrin</surname><given-names>EL</given-names></name><name><surname>Amiri</surname><given-names>F</given-names></name><name><surname>Benkirane</surname><given-names>K</given-names></name><name><surname>Iglarz</surname><given-names>M</given-names></name><name><surname>Diep</surname><given-names>QN</given-names></name></person-group>. <article-title>Peroxisome proliferator-activated
receptors: vascular and cardiac effects in hypertension</article-title>.
<source>Hypertension</source><year>2003</year>. <volume>42</volume>:
<fpage>664</fpage>&#x02013;<lpage>668</lpage>.
doi: <pub-id pub-id-type="doi">10.1161/01.HYP.0000084370.74777.B6</pub-id><pub-id pub-id-type="pmid">12874098</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Leibovitz</surname><given-names>E</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group>. <article-title>PPAR activation: a new target for the treatment of
hypertension</article-title>. <source>J Cardiovasc Pharmacol</source><year>2007</year>. <volume>50</volume>:
<fpage>120</fpage>&#x02013;<lpage>125</lpage>.
doi: <pub-id pub-id-type="doi">10.1097/FJC.0b013e318062153b</pub-id><pub-id pub-id-type="pmid">17703128</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Benson</surname><given-names>SC</given-names></name><name><surname>Pershadsingh</surname><given-names>HA</given-names></name><name><surname>Ho</surname><given-names>CI</given-names></name><etal>et al</etal></person-group><article-title>Identification of telmisartan as a
unique angiotensin II receptor antagonist with selective PPARgamma-modulating
activity</article-title>. <source>Hypertension</source><year>2004</year>. <volume>43</volume>:
<fpage>993</fpage>&#x02013;<lpage>1002</lpage>.
doi: <pub-id pub-id-type="doi">10.1161/01.HYP.0000123072.34629.57</pub-id><pub-id pub-id-type="pmid">15007034</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Pershadsingh</surname><given-names>HA</given-names></name><name><surname>Kurtz</surname><given-names>TW</given-names></name></person-group>. <article-title>Insulin-sensitizing effects of telmisartan: implications
for treating insulin-resistant hypertension and cardiovascular disease</article-title>.
<source>Diabetes Care</source><year>2004</year>. <volume>27</volume>: <fpage>1015</fpage>.
doi: <pub-id pub-id-type="doi">10.2337/diacare.27.4.1015</pub-id><pub-id pub-id-type="pmid">15047668</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Meinders</surname><given-names>AE</given-names></name><name><surname>Toornvliet</surname><given-names>AC</given-names></name></person-group>, <person-group><name><surname>Pijl</surname><given-names>H</given-names></name></person-group>. <article-title>Leptin</article-title>. <source>Neth J Med</source><year>1996</year>. <volume>49</volume>:
<fpage>247</fpage>&#x02013;<lpage>252</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/S0300-2977(96)00039-3</pub-id><pub-id pub-id-type="pmid">8990865</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Girard</surname><given-names>J</given-names></name></person-group>. <article-title>Is leptin the link between obesity and insulin
resistance?</article-title><source>Diabetes Metab</source><year>1997</year>. <volume>23</volume> (Suppl 3): <fpage>16</fpage>&#x02013;<lpage>24</lpage>.
<pub-id pub-id-type="pmid">9342538</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Usui</surname><given-names>I</given-names></name><name><surname>Fujisaka</surname><given-names>S</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Telmisartan reduced blood pressure and
HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic
patients</article-title>. <source>Diabetes Res Clin Pract</source><year>2007</year>. <volume>77</volume>:
<fpage>210</fpage>&#x02013;<lpage>214</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.diabres.2006.11.014</pub-id><pub-id pub-id-type="pmid">17240472</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Clasen</surname><given-names>R</given-names></name><name><surname>Schupp</surname><given-names>M</given-names></name><name><surname>Foryst-Ludwig</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>PPARgamma-activating angiotensin
type-1 receptor blockers induce adiponectin</article-title>.
<source>Hypertension</source><year>2005</year>. <volume>46</volume>:
<fpage>137</fpage>&#x02013;<lpage>143</lpage>.
doi: <pub-id pub-id-type="doi">10.1161/01.HYP.0000168046.19884.6a</pub-id><pub-id pub-id-type="pmid">15939809</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Araki</surname><given-names>K</given-names></name><name><surname>Masaki</surname><given-names>T</given-names></name><name><surname>Katsuragi</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Telmisartan prevents obesity and
increases the expression of uncoupling protein 1 in diet-induced obese
mice</article-title>. <source>Hypertension</source><year>2006</year>. <volume>48</volume>:
<fpage>51</fpage>&#x02013;<lpage>57</lpage>.
doi: <pub-id pub-id-type="doi">10.1161/01.HYP.0000225402.69580.1d</pub-id><pub-id pub-id-type="pmid">16717145</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Benndorf</surname><given-names>RA</given-names></name><name><surname>Rudolph</surname><given-names>T</given-names></name><name><surname>Appel</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Telmisartan improves insulin
sensitivity in nondiabetic patients with essential hypertension</article-title>.
<source>Metabolism</source><year>2006</year>. <volume>55</volume>:
<fpage>1159</fpage>&#x02013;<lpage>1164</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.metabol.2006.04.013</pub-id><pub-id pub-id-type="pmid">16919533</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Ichikawa</surname><given-names>Y</given-names></name></person-group>. <article-title>Comparative effects of telmisartan and valsartan on
insulin resistance in hypertensive patients with metabolic syndrome</article-title>.
<source>Intern Med</source><year>2007</year>; <volume>46</volume>:
<fpage>1331</fpage>&#x02013;<lpage>1336</lpage>.
doi: <pub-id pub-id-type="doi">10.2169/internalmedicine.46.7173</pub-id><pub-id pub-id-type="pmid">17827829</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Takizawa</surname><given-names>H</given-names></name><name><surname>Ura</surname><given-names>N</given-names></name><name><surname>Saitoh</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Gender difference in the relationships
among hyperleptinemia, hyperinsulinemia, and hypertension</article-title>. <source>Clin
Exp Hypertens</source><year>2001</year>. <volume>23</volume>:
<fpage>357</fpage>&#x02013;<lpage>368</lpage>.
doi: <pub-id pub-id-type="doi">10.1081/CEH-100102673</pub-id><pub-id pub-id-type="pmid">11349826</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Usui</surname><given-names>I</given-names></name><name><surname>Fujisaka</surname><given-names>S</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Telmisartan reduced blood pressure and
HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic
patients</article-title>. <source>Diabetes Res Clin Pract</source><year>2007</year>. <volume>77</volume>:
<fpage>210</fpage>&#x02013;<lpage>214</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.diabres.2006.11.014</pub-id><pub-id pub-id-type="pmid">17240472</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Nagel</surname><given-names>JM</given-names></name><name><surname>Tietz</surname><given-names>AB</given-names></name><name><surname>G&#x000f6;ke</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>The effect of telmisartan on glucose
and lipid metabolism in nondiabetic, insulin-resistant subjects</article-title>.
<source>Metabolism</source><year>2006</year>. <volume>55</volume>:
<fpage>1149</fpage>&#x02013;<lpage>1154</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.metabol.2006.04.011</pub-id><pub-id pub-id-type="pmid">16919531</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Moriuchi</surname><given-names>A</given-names></name><name><surname>Yamasaki</surname><given-names>H</given-names></name><name><surname>Shimamura</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Induction of human adiponectin gene
transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma
activation</article-title>. <source>Biochem Biophys Res Commun</source><year>2007</year>. <volume>356</volume>:
<fpage>1024</fpage>&#x02013;<lpage>1030</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2007.03.084</pub-id><pub-id pub-id-type="pmid">17399685</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Koulouris</surname><given-names>S</given-names></name><name><surname>Symeonides</surname><given-names>P</given-names></name><name><surname>Triantafyllou</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Comparison of the effects of ramipril
versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and
oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes
mellitus</article-title>. <source>Am J Cardiol</source><year>2005</year>. <volume>95</volume>:
<fpage>1386</fpage>&#x02013;<lpage>1388</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.amjcard.2005.01.092</pub-id><pub-id pub-id-type="pmid">15904653</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Imaizumi</surname><given-names>T</given-names></name></person-group>. <article-title>Advanced glycation end products (AGEs) and diabetic
vascular complications</article-title>. <source>Curr Diabetes Rev</source><year>2005</year>. <volume>1</volume>:
<fpage>93</fpage>&#x02013;<lpage>106</lpage>.
doi: <pub-id pub-id-type="doi">10.2174/1573399052952631</pub-id><pub-id pub-id-type="pmid">18220586</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Telmisartan, an angiotensin II type 1
receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte
chemoattractant protein-1 expression in mesangial cells through downregulation of
receptor for AGEs via peroxisome proliferator-activated receptor-gamma
activation</article-title>. <source>J Int Med Res</source><year>2007</year>. <volume>35</volume>:
<fpage>482</fpage>&#x02013;<lpage>489</lpage>.
doi: <pub-id pub-id-type="doi">10.1177/147323000703500407</pub-id><pub-id pub-id-type="pmid">17697525</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Telmisartan inhibits expression of a
receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed
endothelial cells and decreases serum levels of soluble RAGE in patients with essential
hypertension</article-title>. <source>Microvasc Res</source><year>2005</year>. <volume>70</volume>:
<fpage>137</fpage>&#x02013;<lpage>141</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.mvr.2005.10.002</pub-id><pub-id pub-id-type="pmid">16271939</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Telmisartan inhibits AGE-induced
C-reactive protein production through downregulation of the receptor for AGE via
peroxisome proliferator-activated receptor-gamma activation</article-title>.
<source>Diabetologia</source><year>2006</year>. <volume>49</volume>:
<fpage>3094</fpage>&#x02013;<lpage>3099</lpage>.
doi: <pub-id pub-id-type="doi">10.1007/s00125-006-0437-7</pub-id><pub-id pub-id-type="pmid">17004092</pub-id></mixed-citation></ref></ref-list></back></article>